PRCT Stock Overview
A surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
PROCEPT BioRobotics Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$81.46 |
52 Week High | US$85.81 |
52 Week Low | US$24.83 |
Beta | 1.0 |
11 Month Change | 31.66% |
3 Month Change | 27.08% |
1 Year Change | 151.11% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 94.23% |
Recent News & Updates
Procept BioRobotics: Risk Capital Unlock With FDA Hydros Approval
Aug 27Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects As Shares Rocket 28%
Aug 25Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results
Aug 04Recent updates
Procept BioRobotics: Risk Capital Unlock With FDA Hydros Approval
Aug 27Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects As Shares Rocket 28%
Aug 25Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results
Aug 04PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce
May 21The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)
Apr 05US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results
Mar 01Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt
Feb 07Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher
Dec 14Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?
Feb 27Procept Biorobotics announces $52M debt refinancing
Oct 10Providence announces national contract for PROCEPT Biorobotics Aquabeam Systems
Sep 19Procept BioRobotics Has Resources To Ramp Up Commercialization
Sep 01Procept: Leveraging A Novel Water-Based System For Enlarged Prostate Treatment
May 26Need To Know: Analysts Are Much More Bullish On PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Revenues
May 10PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported, And Analysts Assigned A US$41.00 Price Target
Mar 10Shareholder Returns
PRCT | US Medical Equipment | US Market | |
---|---|---|---|
7D | 25.3% | 2.1% | 0.6% |
1Y | 151.1% | 10.2% | 22.9% |
Return vs Industry: PRCT exceeded the US Medical Equipment industry which returned 11.6% over the past year.
Return vs Market: PRCT exceeded the US Market which returned 24.9% over the past year.
Price Volatility
PRCT volatility | |
---|---|
PRCT Average Weekly Movement | 10.0% |
Medical Equipment Industry Average Movement | 8.6% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.1% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PRCT's share price has been volatile over the past 3 months.
Volatility Over Time: PRCT's weekly volatility (10%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 626 | Reza Zadno | www.procept-biorobotics.com |
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH.
PROCEPT BioRobotics Corporation Fundamentals Summary
PRCT fundamental statistics | |
---|---|
Market cap | US$4.05b |
Earnings (TTM) | -US$103.71m |
Revenue (TTM) | US$176.58m |
24.0x
P/S Ratio-40.8x
P/E RatioIs PRCT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PRCT income statement (TTM) | |
---|---|
Revenue | US$176.58m |
Cost of Revenue | US$79.93m |
Gross Profit | US$96.65m |
Other Expenses | US$200.35m |
Earnings | -US$103.71m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -2.00 |
Gross Margin | 54.73% |
Net Profit Margin | -58.73% |
Debt/Equity Ratio | 21.2% |
How did PRCT perform over the long term?
See historical performance and comparison